Tumor Necrosis Factor Soluble Receptors Circulate During Experimental and Clinical Inflammation and Can Protect Against Excessive Tumor Necrosis Factor Alpha in Vitro and in Vivo

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1992 Jun 1

PMID 1317575

Citations 190

Authors

K J Van Zee

T Kohno

E FISCHER

C S Rock

L L Moldawer

S F Lowry

Affiliations

Soon will be listed here.

Abstract

Tumor necrosis factor alpha (TNF alpha), a primary mediator of systemic responses to sepsis and infection, can be injurious to the organism when present in excessive quantities. Here we report that two types of naturally occurring soluble TNF receptors (sTNFR-I and sTNFR-II) circulate in human experimental endotoxemia and in critically ill patients and demonstrate that they neutralize TNF alpha-induced cytotoxicity and immunoreactivity in vitro. Utilizing immunoassays that discriminate between total sTNFR-I and sTNFR-I not bound to TNF alpha, we show that sTNFR-I-TNF alpha complexes may circulate even in the absence of detectable free TNF alpha. To investigate the therapeutic possibilities of sTNFR-I, recombinant protein was administered to nonhuman primates with lethal bacteremia and found to attenuate hemodynamic collapse and cytokine induction. We conclude that soluble receptors for TNF alpha are inducible in inflammation and circulate at levels sufficient to block the in vitro cytotoxicity associated with TNF alpha levels observed in nonlethal infection. Administration of sTNFR-I can prevent the adverse pathologic sequelae caused by the exaggerated TNF alpha production observed in lethal sepsis.

Citing Articles

Melatonin, an Antitumor Necrosis Factor Therapy.

Alvarez-Lopez A, Cruz-Chamorro I, Lardone P, Bejarano I, Aspiazu-Hinostroza K, Ponce-Espana E J Pineal Res. 2024; 77(1):e70025.

PMID: 39740227 PMC: 11685806. DOI: 10.1111/jpi.70025.

CD137-expressing regulatory T cells in cancer and autoimmune diseases.

Lee K, Mei Y, Liu H, Schwarz H Mol Ther. 2024; 33(1):51-70.

PMID: 39668561 PMC: 11764688. DOI: 10.1016/j.ymthe.2024.12.010.

Immune markers of severe acute pancreatitis.

Lee P, Papachristou G, Speake C, Lacy-Hulbert A Curr Opin Gastroenterol. 2024; 40(5):389-395.

PMID: 38967941 PMC: 11305979. DOI: 10.1097/MOG.0000000000001053.

An ImmunoFET Coupled with an Immunomagnetic Preconcentration Technique for the Sensitive EIS Detection of HF Biomarkers.

Ben Halima H, Zine N, Nemeir I, Pfeiffer N, Heuberger A, Bausells J Micromachines (Basel). 2024; 15(3).

PMID: 38542544 PMC: 10972101. DOI: 10.3390/mi15030296.

Therapeutic effect of adipose-derived mesenchymal stem cells in a porcine model of abdominal sepsis.

Velez-Pinto J, Garcia-Arranz M, Garcia-Bernal D, Garcia Gomez-Heras S, Villarejo-Campos P, Garcia-Hernandez A Stem Cell Res Ther. 2023; 14(1):365.

PMID: 38087374 PMC: 10717819. DOI: 10.1186/s13287-023-03588-x.

References

LESSLAUER W, Tabuchi H, Gentz R, Brockhaus M, Schlaeger E, Grau G . Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol. 1991; 21(11):2883-6. DOI: 10.1002/eji.1830211134. View

Knaus W, Draper E, Wagner D, Zimmerman J . APACHE II: a severity of disease classification system. Crit Care Med. 1985; 13(10):818-29. View

Engelmann H, Novick D, Wallach D . Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem. 1990; 265(3):1531-6. View

Loetscher H, Pan Y, Lahm H, Gentz R, Brockhaus M, Tabuchi H . Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell. 1990; 61(2):351-9. DOI: 10.1016/0092-8674(90)90815-v. View

Schall T, Lewis M, Koller K, Lee A, Rice G, Wong G . Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell. 1990; 61(2):361-70. DOI: 10.1016/0092-8674(90)90816-w. View

Smith C, Davis T, Anderson D, Solam L, Beckmann M, Jerzy R . A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science. 1990; 248(4958):1019-23. DOI: 10.1126/science.2160731. View

Seckinger P, Zhang J, Hauptmann B, Dayer J . Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor. Proc Natl Acad Sci U S A. 1990; 87(13):5188-92. PMC: 54287. DOI: 10.1073/pnas.87.13.5188. View

Porteu F, Nathan C . Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med. 1990; 172(2):599-607. PMC: 2188336. DOI: 10.1084/jem.172.2.599. View

Gray P, Barrett K, Chantry D, Turner M, Feldmann M . Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein. Proc Natl Acad Sci U S A. 1990; 87(19):7380-4. PMC: 54750. DOI: 10.1073/pnas.87.19.7380. View

10.

Kohno T, Brewer M, Baker S, Schwartz P, King M, Hale K . A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci U S A. 1990; 87(21):8331-5. PMC: 54949. DOI: 10.1073/pnas.87.21.8331. View

11.

Gatanaga T, Hwang C, Kohr W, Cappuccini F, Lucci 3rd J, Jeffes E . Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci U S A. 1990; 87(22):8781-4. PMC: 55043. DOI: 10.1073/pnas.87.22.8781. View

12.

Spinas G, Bloesch D, KAUFMANN M, Keller U, Dayer J . Induction of plasma inhibitors of interleukin 1 and TNF-alpha activity by endotoxin administration to normal humans. Am J Physiol. 1990; 259(5 Pt 2):R993-7. DOI: 10.1152/ajpregu.1990.259.5.R993. View

13.

Marano M, Fong Y, Moldawer L, Wei H, Calvano S, Tracey K . Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. Surg Gynecol Obstet. 1990; 170(1):32-8. View

14.

Fong Y, Marano M, Moldawer L, Wei H, Calvano S, KENNEY J . The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest. 1990; 85(6):1896-904. PMC: 296656. DOI: 10.1172/JCI114651. View

15.

KENNEY J, Masada M, Eugui E, Delustro B, Mulkins M, Allison A . Monoclonal antibodies to human recombinant interleukin 1 (IL 1)beta: quantitation of IL 1 beta and inhibition of biological activity. J Immunol. 1987; 138(12):4236-42. View

16.

Moldawer L, Andersson C, Gelin J, Lundholm K . Regulation of food intake and hepatic protein synthesis by recombinant-derived cytokines. Am J Physiol. 1988; 254(3 Pt 1):G450-6. DOI: 10.1152/ajpgi.1988.254.3.G450. View

17.

Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D . A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem. 1989; 264(20):11974-80. View

18.

Fong Y, Tracey K, Moldawer L, Hesse D, Manogue K, KENNEY J . Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med. 1989; 170(5):1627-33. PMC: 2189514. DOI: 10.1084/jem.170.5.1627. View

19.

Seckinger P, Isaaz S, Dayer J . A human inhibitor of tumor necrosis factor alpha. J Exp Med. 1988; 167(4):1511-6. PMC: 2188924. DOI: 10.1084/jem.167.4.1511. View

20.

Michie H, Manogue K, Spriggs D, Revhaug A, ODwyer S, Dinarello C . Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988; 318(23):1481-6. DOI: 10.1056/NEJM198806093182301. View